TY - JOUR
T1 - Comparison of antiviral compounds against human herpesvirus 6 and 7
AU - Yoshida, Mariko
AU - Yamada, Masao
AU - Tsukazaki, Takashi
AU - Chatterjee, Subhendra
AU - Lakeman, Fred D.
AU - Nii, Shiro
AU - Whitley, Richard J.
N1 - Funding Information:
We thank Dr T. Yamagata and his co-workers for their support. Work performed and reported by the authors was supported by Contracts NOI-AI-15113, NOI-AI-12667 from the Virology Branch, DMID, the National Institute of Allergy and Infectious Diseases, a grant from the Division of Research Resources (RR-032) from the National Institutes of Health, Bristol Myers Squibb Unrestricted Infectious Disease Award, a grant from the state of Alabama, USA, and a grant-in-aid from the Ministry of Health and Welfare, Japan.
PY - 1998/12
Y1 - 1998/12
N2 - Four classes of antiviral compounds were evaluated for inhibitory activity against two variants of human herpesvirus 6 (HHV-6A and -6B) and human herpesvirus 7 (HHV-7). These included: (1) a pyrophosphate analog, phosphonoformic acid (PFA); (2) beta-guanine analogs, 9-(2-hydroxyethoxymethyl)guanine (acyclovir or ACV), 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine (ganciclovir or GCV) and 9-(4-hydroxy-3-hydroxy-3-hydroxymethylbutylyl)guanine (penciclovir or PCV); (3) acyclic nucleoside phosphonates, (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine [cidofovir or (S)-HPMPC] and its cyclic derivative (S)-cyclic-HPMPC (cHPMPC), 9-[[2-hydroxy-1-phosphonomethoxy)ethoxy]methyl]guanine (HPMEMG) and 9-[(2-phosphonylmethoxy)ethyl]-2,6-diaminopurine (PMEDAP), and the seven other related compounds; and (4) a series of benzimidazole ribonucleosides, including 2-bromo-5,6-dichloro-1-(beta-d-ribofuranosyl)benzimidazole (BDCRB). End-point inhibitory concentration (EPC) and 50% effective inhibitory concentration (EC50) values were determined by a dot-blot antigen detection method in cord blood mononuclear cells infected with HHV-6A, HHV-6B or HHV-7 at a multiplicity of infection of 0.004 CCID50/cell. (S)-HPMPC and cHPMPC had an EC50 value of approximately 0.3 μg/ml for HHV-6A, 1.2 μg/ml for HHV-6B and 3.0 μg/ml for HHV-7. These compounds were the most active of those tested against each virus. The EC50 value of GCV for HHV-6A was 0.65 μg/ml, 1.33 μg/ml for HHV-6B, and >7 μg/ml for HHV-7. The EC50 values of ACV and PCV were approximately 6-8 μg/ml for HHV-6A, 16-24 μg/ml for HHV-6B and 121-128 μg/ml for HHV-7. These drugs were the least active. The sensitivity of HHV-7 to the guanine analogs was different from HHV-6, suggesting a difference in selectivity of specific viral enzymes. Copyright (C) 1998 Elsevier Science B.V.
AB - Four classes of antiviral compounds were evaluated for inhibitory activity against two variants of human herpesvirus 6 (HHV-6A and -6B) and human herpesvirus 7 (HHV-7). These included: (1) a pyrophosphate analog, phosphonoformic acid (PFA); (2) beta-guanine analogs, 9-(2-hydroxyethoxymethyl)guanine (acyclovir or ACV), 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine (ganciclovir or GCV) and 9-(4-hydroxy-3-hydroxy-3-hydroxymethylbutylyl)guanine (penciclovir or PCV); (3) acyclic nucleoside phosphonates, (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine [cidofovir or (S)-HPMPC] and its cyclic derivative (S)-cyclic-HPMPC (cHPMPC), 9-[[2-hydroxy-1-phosphonomethoxy)ethoxy]methyl]guanine (HPMEMG) and 9-[(2-phosphonylmethoxy)ethyl]-2,6-diaminopurine (PMEDAP), and the seven other related compounds; and (4) a series of benzimidazole ribonucleosides, including 2-bromo-5,6-dichloro-1-(beta-d-ribofuranosyl)benzimidazole (BDCRB). End-point inhibitory concentration (EPC) and 50% effective inhibitory concentration (EC50) values were determined by a dot-blot antigen detection method in cord blood mononuclear cells infected with HHV-6A, HHV-6B or HHV-7 at a multiplicity of infection of 0.004 CCID50/cell. (S)-HPMPC and cHPMPC had an EC50 value of approximately 0.3 μg/ml for HHV-6A, 1.2 μg/ml for HHV-6B and 3.0 μg/ml for HHV-7. These compounds were the most active of those tested against each virus. The EC50 value of GCV for HHV-6A was 0.65 μg/ml, 1.33 μg/ml for HHV-6B, and >7 μg/ml for HHV-7. The EC50 values of ACV and PCV were approximately 6-8 μg/ml for HHV-6A, 16-24 μg/ml for HHV-6B and 121-128 μg/ml for HHV-7. These drugs were the least active. The sensitivity of HHV-7 to the guanine analogs was different from HHV-6, suggesting a difference in selectivity of specific viral enzymes. Copyright (C) 1998 Elsevier Science B.V.
KW - Antiviral compounds
KW - Benzimidazole ribonucleosides
KW - Dot-blot method
KW - Human herpesvirus 6
KW - Human herpesvirus 7
KW - Virus replication
UR - http://www.scopus.com/inward/record.url?scp=0032402266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032402266&partnerID=8YFLogxK
U2 - 10.1016/S0166-3542(98)00049-7
DO - 10.1016/S0166-3542(98)00049-7
M3 - Article
C2 - 9864048
AN - SCOPUS:0032402266
VL - 40
SP - 73
EP - 84
JO - Antiviral Research
JF - Antiviral Research
SN - 0166-3542
IS - 1-2
ER -